NERV

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Luthringer RemyDirector, Officer: CEO --1.7M shares Grant / ExerciseJun 3, 2026 $7.9M1.7M shares $4.68 $5.00
Ahlholm Frederick WSVP, CFO And Secretary --680k shares Grant / ExerciseJun 3, 2026 $3.2M680k shares $4.68 $5.00
Hasler Hans PeterDirector --50k shares Grant / ExerciseJun 3, 2026 $234.0K50k shares $4.68 $5.00
Van Heek G JanDirector --50k shares Grant / ExerciseJun 3, 2026 $234.0K50k shares $4.68 $5.00
Kaul InderjitDirector --50k shares Grant / ExerciseJun 3, 2026 $234.0K50k shares $4.68 $5.00
Kupfer DavidDirector --50k shares Grant / ExerciseJun 3, 2026 $234.0K50k shares $4.68 $5.00

News

globenewswire.comMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programsglobenewswire.comJun 1

zacks.comAll You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buyzacks.comMay 20

zacks.comMinerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerzacks.comMay 20

globenewswire.comMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conferenceglobenewswire.comMay 18

Trade NERV

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

CEO: Remy Luthringer
IPO Date: Jul 1, 2014

Market Data

Open: $4.67
High: $4.87
Low: $4.57
Volume: 96.3K
52W High: $12.46
52W Low: $1.57

Valuation

Market Cap: $33M
Enterprise Value: $65M

Financials

Free Cash Flow: $-14B
Revenue: $0
Net Income: $-293M
Cash: $82M
Debt: $65M

Events

EarningsAug 13

EPS est. -0.19333